The Omicron variant may cause a wave of infections as soon as January 2022; Pfizer’s COVID-19 pill, Paxlovid, was found to reduce the risk of hospitalization and death by 88%; JPMorgan Health Care Conference will move to a virtual format after receiving pressure from major drug companies.
Based on data from the CDC, US federal health officials warned that the Omicron variant of COVID-19 is spreading rapidly across the country and may cause a wave of infections as soon as January, The Washington Post reported. According to the CDC, Omicron prevalence multiplied by 7 in a single week while Delta cases are still increasing. If this trend continues as expected, the nation will likely see another surge in cases that could overwhelm hospitals. Because existing vaccines and booster shots are currently effective against the newest COVID-19 variant, health officials say there is no need for an Omicron-specific vaccine.
The Pfizer COVID-19 pill sold as Paxlovid is likely to be an effective treatment against the Omicron variant and could be available in the United States before 2022, The New York Times reported. Pfizer announced that the pill fights against severe disease and was found to reduce the risk of hospitalization and death by 88% when given to unvaccinated people at high risk of severe COVID-19 within 5 days after symptoms started. If FDA approved, Paxlovid could potentially reduce the number of hospitalizations predicted to occur as soon as January due to Omicron, but the pill will still be limited in supply at first.
Biotech’s biggest annual conference, the JPMorgan Health Care Conference, moved to a virtual format after receiving pressure from major drug companies, STAT News reported. JPMorgan emailed those registered for the January 2022 conference saying the health and safety of the company’s clients and employees are most important, especially during the ongoing COVID-19 pandemic and the spread of Omicron. The decision was made after companies such as Moderna and Amgen announced they would not attend the meeting if it was in person, which normally hosts around 10,000 attendees. Originally, only those vaccinated against COVID-19 would be allowed to attend the conference in San Francisco with masks and some sessions were already scheduled to be virtual, but now the conference is completely virtual.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More